The Journal of Experimental Medicine
Track the topics, authors and articles important to you
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online 8 March 2004 doi:10.1084/jem.20031591
Rockefeller University Press, 0022-1007 $8.00
JEM, Volume 199, Number 6, 775-784
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 384K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ahonen, C. L.
Right arrow Articles by Kedl, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ahonen, C. L.
Right arrow Articles by Kedl, R. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Combined TLR and CD40 Triggering Induces Potent CD8+ T Cell Expansion with Variable Dependence on Type I IFN

Cory L. Ahonen1, Christie L. Doxsee3, Sean M. McGurran3, Tony R. Riter3, William F. Wade1, Richard J. Barth2, John P. Vasilakos3, Randolph J. Noelle1, and Ross M. Kedl3

1 Department of Microbiology and Immunology, and 2 Department of Surgery, Dartmouth Medical School, Lebanon, NH 03756
3 Department of Pharmacology, 3M Pharmaceuticals, St. Paul, MN 55144

Address correspondence to Ross M. Kedl, 3M Pharmaceuticals, 3M Center, Bldg. 270-02-S-06, St. Paul, MN 55144. Phone: (651) 733-4821; Fax: (651) 737-5886; email: rmkedl{at}mmm.com

Toll-like receptors are important in the activation of innate immunity, and CD40 is a molecule critical for many T and B cell responses. Whereas agonists for either pathway have been used as vaccine adjuvants, we show that a combination of Toll-like receptor (TLR)7 and CD40 agonists synergize to stimulate CD8+ T cell responses 10–20-fold greater than the use of either agonist alone. Antigen-specific CD8+ T cells elicited from combination CD40/TLR7 treatment demonstrated both lytic activities and interferon (IFN){gamma} production and an enhanced secondary response to antigenic challenge. Agonists for TLRs 2/6, 3, 4, and 9 also synergized with CD40 stimulation, demonstrating that synergy with the CD40 pathway is a property of TLR-derived stimuli in general. The CD8+ T cell expansion induced by CD40/TLR7 triggering was independent of CD4+ T cells, IFN{gamma}, and IL-12 but dependent on B7-mediated costimulation and surprisingly on type I IFN. These studies provide the rational basis for the use of TLR and CD40 agonists together as essential adjuvants to optimize vaccines designed to elicit protective or therapeutic immunity.

Key Words: Toll like receptor • TLR7 • CD40 • CD8 • T cell

C.L. Ahonen and C.L. Doxsee contributed equally to this work.

Abbreviations used in this paper: IRM, immune response modifier; TLR, Toll-like receptor.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS